Cancer cells are notorious for their relentless growth and survival under adverse conditions such as nutrient scarcity and hypoxia. To manage these hostile microenvironments, they activate a cellular survival mechanism known as the integrated stress response (ISR). This pathway adapts cellular functions to stressors and is crucial for cancer progression. At the heart of ISR activation is the transcription factor Activating Transcription Factor 4 (ATF4), which orchestrates the expression of numerous genes that collectively enhance cancer cell survival, metabolism, and proliferation under stress.

The NYU Langone research team focused on the relationship between ISR and immune evasion, delving into how ATF4 influences tumor-immune interactions. Their findings revealed that ATF4 stimulates the secretion of LCN2, a small soluble protein, which is secreted outside the cancer cells and plays a pivotal role in subverting the immune response. LCN2 works by modulating the behavior of macrophages—immune cells abundant in the tumor microenvironment—shifting them towards an immunosuppressive phenotype that actively excludes cytotoxic T cells, which are essential for tumor eradication.

This immunosuppressive shift orchestrated by LCN2 essentially builds a protective barrier, preventing immune cells from penetrating the tumor mass and attacking malignant cells. Unlike ATF4, which functions intracellularly and is thus challenging to target pharmacologically, LCN2 exists in the extracellular space where it is more accessible to therapeutic intervention. The researchers harnessed this feature to develop an antibody that neutralizes LCN2, effectively disarming its immune-suppressive capabilities.

Preclinical trials in mouse models of lung and pancreatic cancers demonstrated that blocking LCN2 not only halted tumor progression but also facilitated a resurgence of immune cell infiltration, especially reactivating the tumor-killing T cells. These results were even more compelling when the anti-LCN2 antibody was combined with existing immunotherapies, significantly prolonging survival in aggressive cancer models. This synergistic effect underscores the potential for LCN2-targeted therapies to overcome resistance mechanisms that have limited the efficacy of conventional immune checkpoint inhibitors.

Further substantiating the clinical relevance, tumor sample analyses from over a hundred lung cancer patients and several dozen pancreatic cancer patients showed a clear correlation between elevated LCN2 levels and poorer survival outcomes. Patients exhibiting high LCN2 expression had a median survival rate markedly lower than those with minimal expression, suggesting that LCN2 might serve as a prognostic biomarker and a determinant of immunotherapy responsiveness.

The mechanistic insight into how stressed cancer cells enlist LCN2 to manipulate the immune microenvironment opens a novel front in oncology research. It shifts the paradigm from solely focusing on tumor cells to considering how cancer-related stress pathways influence immune cell behavior, particularly macrophages. Understanding this crosstalk is essential for designing interventions that restore immune surveillance and enhance the effectiveness of immunotherapies.

The study was spearheaded by Dr. Thales Papagiannakopoulos and Dr. Shohei Koide, experts in pathology and molecular pharmacology, respectively. They emphasized that while their current research centered on lung and pancreatic cancers, the involvement of ISR and LCN2 in immune evasion could be a broader phenomenon applicable to various cancer types that presently resist immunotherapy. Their ongoing work aims to investigate this possibility, potentially extending the therapeutic benefits of LCN2 inhibition.

What sets this discovery apart is the dual advantage of targeting LCN2: it not only disrupts a key immune escape mechanism but also sensitizes tumors to existing immunotherapeutic agents. This dual-attack strategy may pave the way for personalized cancer treatments that adapt to the tumor’s molecular stress profile, thwarting its ability to hide from immune detection.

The implications of these findings extend beyond therapeutics into the realm of cancer diagnostics. LCN2 levels in tumors could become part of the diagnostic arsenal to stratify patients according to their likelihood of responding to immunotherapies. Such precision medicine approaches are vital in optimizing clinical outcomes and avoiding unnecessary treatments.

Funding for this pivotal research came from multiple National Institutes of Health grants, the American Cancer Society, the National Science Foundation, and several philanthropic organizations, underscoring the high priority and collaborative nature of cancer research. The authors have declared relationships with various pharmaceutical and biotech companies, managed in accordance with institutional policies to ensure scientific integrity.

NYU Langone Health’s integrated system of research, clinical care, and education provides a fertile environment for such high-impact studies, reflecting its standing as a leading academic medical center. The Perlmutter Cancer Center, central to this research, continues to push the boundaries of knowledge to develop next-generation cancer therapies.

As the oncology community digests these findings, the future looks promising for exploiting the ISR-LCN2 axis to unlock tumors from their immunosuppressive cocoons. This study not only advances scientific understanding but also inspires a new wave of therapeutic innovations aimed at tipping the balance in favor of the immune system and improving survival for patients battling some of the most formidable cancers.

Subject of Research: Human tissue samples

Article Title: ‘The integrated stress response promotes immune evasion through lipocalin 2’

News Publication Date: 18-Feb-2026

Web References:
DOI Link to Article

Keywords: Cancer, Transcription factors

Central to their discovery is the identification of a complex reprogramming of neutrophils—white blood cells that serve as primary responders in the innate immune system—within the tumor microenvironment of bone metastases. Unlike their typical mature counterparts that aid in attacking tumors, these neutrophils are converted into an immature, immunosuppressive state. This altered functional phenotype, the researchers report in the exacting pages of Cancer Cell, severely blunts the anti-tumor immune response. The culprit behind this neutrophil reprogramming is a protein called Dickkopf-related protein 1 (DKK1), which is abundantly produced by the bone tumor niche.

DKK1, previously implicated in bone biology and cancer progression, acts as a molecular architect that remodels the cellular landscape to favor tumor persistence. Through a sophisticated series of biochemical signals, DKK1 disrupts neutrophil maturation, which consequently fosters a tumor-friendly microenvironment. This aberrant state is marked by the production of another molecule, chitinase 3-like 3 (CHI3L3), which exerts potent suppressive effects on cytotoxic CD8+ T cells—the main warriors of the adaptive immune system tasked with identifying and destroying malignant cells.

Previous research has shown neutrophils to be ambivalent players in cancer biology, with their role oscillating between tumor promotion and tumor suppression depending on their specific activation states. The Merghoub and Shi study crucially emphasizes that it is the immature, DKK1-reprogrammed neutrophils that dominate within bone metastases, effectively erecting an immunological shield that thwarts therapies designed to unleash T cell-mediated killing. This insight elucidates a pivotal reason why immune checkpoint blockade therapies, such as anti-PD-1 antibodies, fail to produce significant responses in patients whose cancers have metastasized to the bone.

In meticulously designed mouse models of triple-negative breast cancer metastatic to bone, the researchers demonstrated that blocking DKK1 with a targeted antibody markedly reversed this immune suppression. This intervention allowed neutrophils to mature appropriately, reducing CHI3L3 levels and relieving the inhibition on CD8+ T cells. Remarkably, when DKK1 blockade was combined with immune checkpoint inhibitors, tumors regressed dramatically, with some completely eradicated. These findings provide compelling preclinical evidence that DKK1-targeted therapies could synergize with existing immunotherapies to overcome resistance in bone metastases, a dire unmet clinical need.

Expanding beyond preclinical models, their analyses included patient-derived serum samples from individuals with gastric cancer and bone metastases, where elevated DKK1 levels mirrored those observed in experimental contexts. This translational aspect not only reinforces the relevance of their findings to human disease but also suggests potential biomarkers—DKK1 and CHI3L3—that could stratify patients likely to benefit from combined immunotherapeutic approaches targeting both neutrophils and T cells.

From a mechanistic standpoint, the study delved deep into the intracellular signaling pathways activated by DKK1 that orchestrate neutrophil dysfunction. By pinpointing these molecular conduits, the research identifies multiple potential pharmacological targets beyond DKK1 itself, broadening the horizon for drug development aiming to recalibrate the immune microenvironment in metastatic bone lesions.

This research further challenges the established focus on targeting adaptive immunity alone, emphasizing the critical role of innate immune cells—particularly neutrophils—in shaping therapeutic outcomes. The data argue for an integrated immunotherapeutic strategy that not only reinvigorates T cells but simultaneously reprograms neutrophils away from a suppressive phenotype, thus unleashing a coordinated immune assault on cancer.

The clinical implications are especially promising, given that DKN-01, a DKK1-blocking antibody, is already in clinical trials, accelerating the potential translation of these discoveries into effective treatments. The identification of CHI3L3 and its gene expression signatures as biomarkers opens avenues for precision medicine, enabling oncologists to tailor therapies according to the immune landscape of individual tumors.

The broader significance of this study lies in its illumination of the complex interplay between cancer cells and their microenvironment, specifically within the unique immunosuppressive context of bone metastases. By unveiling the molecular and cellular underpinnings of immunotherapy resistance, this work not only advances our understanding of cancer biology but also offers a tangible path toward improving outcomes for patients grappling with metastatic disease, for whom therapeutic options remain woefully inadequate.

In summation, this rigorous investigation by Merghoub, Shi, and colleagues delineates a novel immunosuppressive axis driven by DKK1-induced neutrophil immaturity within bone metastases. Intervening in this axis restores immune competency, sensitizes tumors to checkpoint blockade, and presents a compelling target for next-generation cancer immunotherapies. Their findings herald a paradigm shift, advocating for the co-targeting of innate and adaptive immunity in combating metastatic cancer, with a profound potential to reshape clinical practice and patient survival.

Subject of Research: Neutrophil reprogramming and immunotherapy resistance in bone metastases mediated by DKK1.

Article Title: DKK1-mediated neutrophil reprogramming fosters immunotherapy resistance in bone metastases.

News Publication Date: August 7, 2025.

Web References:

• Cancer Cell article: https://www.sciencedirect.com/science/article/abs/pii/S1535610825003137?via%3Dihub
• Related neutrophil study: https://www.nature.com/articles/s41422-025-01145-0

Image Credits: Ludwig Cancer Research, image of Taha Merghoub.

Keywords: Health and medicine, Cancer, Immunotherapy, Neutrophils, Bone metastases, DKK1, Tumor microenvironment, CD8+ T cells, Innate immunity, Immune checkpoint blockade.

Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have made a pivotal discovery that could change the dynamics of lung cancer treatment. Their study has identified a crucial RNA-binding protein, known as DEAD-box helicase 54 (DDX54), as the master regulator that inhibits the effectiveness of immunotherapy in patients. This finding could pave the way for innovative approaches to enhance the responsiveness of immune cells, particularly in cases where tumors display resistance to standard treatments. The technology arising from this research has already been transferred to a faculty startup, BioRevert Inc., which is now developing it as a companion therapy, with plans for clinical trials to begin by 2028.

The research team, led by Professor Kwang-Hyun Cho of KAIST’s Department of Bio and Brain Engineering, revealed that DDX54 plays a critical role in lung cancer cells’ ability to evade the immune response. By suppressing DDX54, the researchers noted a marked increase in immune cell infiltration into tumors, leading to a significantly enhanced efficacy of immunotherapy. The research, published in the prestigious Proceedings of the National Academy of Sciences, delineates a new pathway for therapeutic intervention aimed at boosting the effectiveness of immune checkpoint inhibitors, which include anti-PD-1 and anti-PD-L1 antibodies.

Despite the promise of immunotherapy, the low response rates among cancer patients continue to pose a considerable obstacle. To identify potential responders, the FDA recently approved tumor mutational burden (TMB) as a key biomarker for immunotherapy. Cancers that exhibit high mutation rates are generally more amenable to immune checkpoint inhibitors. Nevertheless, even tumors with elevated TMB can sometimes exhibit what is known as an “immune-desert” phenotype, wherein immune cell infiltration is severely restricted, resulting in suboptimal treatment outcomes.

In their investigation, Professor Cho and his research team conducted a comprehensive analysis of transcriptomic and genomic data derived from patients exhibiting immune evasion in lung cancer. This extensive analysis enabled them to uncover DDX54 as a significant factor underlying the resistance to immunotherapy. Their findings indicate that by targeting DDX54, it may be possible to overcome the barrier of immunotherapy resistance, effectively enhancing patient outcomes in previously difficult-to-treat lung tumors.

The research employed advanced systems biology techniques, allowing the team to integrate various high-dimensional data sets to build gene regulatory networks. The identification of DDX54 as a central regulator offers a prospective therapeutic target that could revolutionize the approach to treating this disease. In preclinical trials using a syngeneic mouse model, the suppression of DDX54 resulted in substantial increases in the infiltration of T cells and natural killer (NK) cells, key players in the body’s anti-cancer immune response. Furthermore, this suppression drastically improved the overall response to immunotherapy treatments.

Subsequent experiments employing single-cell transcriptomic and spatial transcriptomic analyses confirmed the effectiveness of targeting DDX54. The combination of DDX54 inhibition with immunotherapy led to encouraging results, with enhanced differentiation of T cells and memory T cells, which are crucial for long-term tumor suppression. Notably, the combination treatment reduced the presence of regulatory T cells and exhausted T cells that typically foster tumor growth.

The mechanisms underlying these changes appear to involve DDX54’s influence on critical signaling pathways, including JAK-STAT, MYC, and NF-κB. This regulatory cascade not only leads to the downregulation of immune-evasive proteins such as CD38 and CD47 but also affects the infiltration of immune cell populations that are pivotal to anti-tumor activity. The findings highlight the potential of DDX54 suppression to alter the tumor microenvironment in a manner conducive to successful immunotherapy.

Professor Cho articulated the significance of their findings by stating that they have, for the first time, identified a master regulatory factor capable of orchestrating immune evasion in lung cancer cells. He emphasized that targeting this factor could lead to a groundbreaking therapeutic strategy aimed at enhancing immune responsiveness in otherwise resistant cancer phenotypes. Through systematic integration of systems biology, combining information technology with biotechnological insights, the research team was able to reveal DDX54’s hidden roles within the complex molecular networks of cancer cells.

The implications of such discoveries are profound, not only for lung cancer treatment but also for potentially broadening the scope of effective immunotherapies across various cancer types. By inducing an immune-activated environment that restores the ability of immune cells to infiltrate cancer tissues, the combination therapy utilizing DDX54 inhibition could substantially enhance the sensitivity of tumors to immunotherapy, particularly in resistant cases.

As research continues into the biological intricacies of cancer-resistance mechanisms, the identification and targeting of key regulatory factors such as DDX54 offer hope for improved therapeutic strategies that leverage the body’s own immune system. The innovative approach adopted by the KAIST research team serves as a beacon for future studies that seek to unravel the complexities of tumor immunology and provide tangible benefits to patients grappling with cancer.

The study culminated in significant peer-reviewed publication in the Proceedings of the National Academy of Sciences on April 2, 2025, highlighting the contributions of Jeong-Ryeol Gong as the first author and Jungeun Lee as a co-first author, with Younghyun Han also contributing to the research effort. With backing from the Ministry of Science and ICT and the National Research Foundation of Korea, the work exemplifies a successful marriage of fundamental research and clinical application, a necessary pathway toward future breakthroughs in cancer treatment technologies.

Driven by a commitment to transform cancer treatment paradigms, this study stands as a testament to the continuing evolution of cancer research, presenting the scientific community with one more piece in the ever-complex puzzle of immunotherapy efficacy and resistance.

Subject of Research: Animal tissue samples
Article Title: DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden
News Publication Date: 2-Apr-2025
Web References: DOI
References: None available
Image Credits: KAIST Laboratory for Systems Biology and Bio-Inspired Engineering
Keywords: DDX54, immunotherapy, lung cancer, tumor mutational burden, immune checkpoint inhibitors, cancer treatment, systems biology, RNA-binding protein

The intricate realms of epigenetics and epitranscriptomics are crucial for understanding the mechanisms that modify gene expression without changing the underlying genetic code. One of these processes involves N6-methyladenosine, or m6A, where methyl groups are added to the N6 position of adenosine in RNA molecules. This modification plays a vital role in enhancing RNA stability, which is crucial for normal cellular functions. However, the removal of these methyl groups by enzymes such as FTO has been shown to facilitate tumor development, highlighting the dual nature of RNA modifications in cancer.

FTO stands out as the first identified m6A demethylase and has been observed to be upregulated in various forms of cancer. A team led by Dr. Yu-Ying He, a respected professor of medicine in the dermatology section at the University of Chicago, undertook a comprehensive study to identify compounds capable of degrading FTO. The implications of targeting FTO for cancer treatment are vast, considering its significant role in obesity-related malignancies.

Interestingly, FTO has drawn researchers’ attention even before its association with RNA modification came to light. In earlier investigations conducted by Dr. He and her colleagues, they found elevated levels of FTO in melanoma, a notoriously aggressive type of skin cancer. Their research highlighted environmental factors, including exposure to UV radiation and arsenic, which contribute to heightened levels of FTO, resulting in decreased RNA modifications in melanoma, thereby fostering tumor growth.

While the search for small molecule FTO inhibitors has unfolded, many of these candidates faced hurdles concerning their clinical utility. Concerns about unknown or undesirable toxicity profiles raised red flags regarding their viability as therapeutic agents. In light of these challenges, Dr. He’s collaboration with Dr. Chuan He, a distinguished professor of chemistry at the University of Chicago, was pivotal. Together, they screened an array of compounds, ultimately identifying vitamin E succinate as a potential FTO degrader.

The safety profile of VES is particularly noteworthy, as it is already widely utilized as a dietary supplement. This characteristic distinguishes it from other small molecule FTO inhibitors that might come with unknown risks. The researchers employed molecular docking techniques to validate their findings, confirming that VES binds effectively to FTO, thereby promoting its degradation. In contrast, other vitamins and derivatives of vitamin E lacked the same effect, emphasizing VES’s unique potential.

Delving deeper into the molecular mechanisms, the researchers established that the degradation of proteins like FTO is typically mediated by E3 ubiquitin ligases. Subsequently, the study identified DTX2 as the E3 ubiquitin ligase involved in facilitating the degradation of FTO in response to VES. This critical finding strengthens the understanding of how VES operates at a molecular level, positioning it as a novel therapeutic candidate in cancer treatment.

The mechanism of action of vitamin E succinate is intriguing; it is comprised of two primary components—succinate and vitamin E. Succinate binds to FTO, while vitamin E binds to DTX2, effectively uniting these two molecules. This interaction facilitates the degradation of FTO, functioning analogously to a molecular glue that brings the necessary players together to initiate the degradation process.

The implications of these findings extend beyond understanding FTO degradation. The research team conducted a series of experiments to decipher how VES could alleviate tumorigenesis and heighten tumor sensitivity to immunotherapy. Their work ultimately demonstrated that VES enhances T-cell mediated cytotoxicity through the intrinsic suppression of FTO within tumors, offering a new angle for enhancing immunotherapeutic strategies.

As a dietary supplement with a well-known safety profile, vitamin E succinate holds immense promise as a therapeutic intervention for cancers characterized by elevated FTO levels, which are often resistant to conventional immunotherapy. This discovery sets the stage for future clinical trials aimed at integrating VES into the treatment protocols of resistant cancer types, potentially improving outcomes for many patients.

The wealth of knowledge from this study conduces to a greater understanding of the multifaceted roles that epitranscriptomics play in cancer biology. Consequently, ongoing research into FTO inhibitors and derivatives stands to contribute significantly toward innovative cancer treatment strategies that more effectively exploit the immune system’s capabilities.

In summary, the identification of vitamin E succinate as a viable FTO degrader represents a landmark moment in cancer research. The synergy between dietary supplements and targeted therapies emphasizes the potential of repurposing existing compounds to address pressing challenges in oncology, particularly in the fight against drug-resistant cancers.

Subject of Research: Vitamin E succinate’s role in FTO degradation and its implications for cancer immunotherapy.
Article Title: Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.
News Publication Date: 17-Dec-2024.
Web References: PNAS Article
References: Research on FTO link to obesity and cancer, Dr. Yu-Ying He’s prior studies on melanoma and environmental factors, collaboration with Dr. Chuan He.
Image Credits: N/A

Keywords: Vitamin E, tumor growth, cancer immunotherapy, FTO, epitranscriptomics.